| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10920090 | Radiotherapy and Oncology | 2005 | 5 Pages |
Abstract
This LTBI and IL-2 regimen was well tolerated, however it cannot be recommended because of its low clinical efficacy. No indication of increased efficacy or altered toxicity was seen using LTBI.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Akmal Safwat, Henrik Schmidt, Lars Bastholt, Kirsten Fode, Susanne Larsen, Ninna Aggerholm, Hans von der Maase,